Urine Reflection of Changes in Blood

  • Menglin LiEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 845)


The most important of nature of biomarker is changes. Blood is under strict homeostatic control which means changes tend to be removed from blood. Urine is a partial filtrate of blood, reflects systemic physiology but with no homeostatic mechanism. However, changes induced directly into the blood can be more sensitively detected in urine than in blood itself. This indicates that urine may serve as a source for more sensitive detection of protein biomarkers than blood.


Change Biomarker Urine Blood 


  1. 1.
    Gao YH (2013) Can urine be the gold mine for biomarker discovery? Sci China Life Sci 56Google Scholar
  2. 2.
    Decramer S, Gonzalez de Peredo A, Breuil B et al (2008) Urine in clinical proteomics. Mol Cell Proteomics 7:1850–1862Google Scholar
  3. 3.
    Yi J, Kim C, Gelfand CA (2007) Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res 6:1768–1781Google Scholar
  4. 4.
    Schaub S, Wilkins J, Weiler T et al (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65:323–332Google Scholar
  5. 5.
    Menglin L, Mindi Z, Youhe G (2013) Changes of proteins induced by anticoagulants can be more sensitively detected in urine rather than plasma. Sci China Life Sci 57(7):649–656Google Scholar
  6. 6.
    Thongboonkerd V, McLeish KR, Arthur JM, Klein JB (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 62:1461–1469Google Scholar
  7. 7.
    Brunzel N (2004) Fundamentals of urine & body fluid analysis, 2nd edn. Saunders, PhiladelphiaGoogle Scholar
  8. 8.
    Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, et al (2003) The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 3:1345–1364Google Scholar
  9. 9.
    Nagaraj N, Mann M (2011) Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J Proteome Res 10:637–645Google Scholar
  10. 10.
    Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH et al (2002) Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 1:947–955Google Scholar
  11. 11.
    Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA et al (2003) Biomarker amplification by serum carrier protein binding. Dis Markers 19:1–10Google Scholar
  12. 12.
    Kentsis A, Monigatti F, Dorff K, Campagne F, Bachur R et al (2009) Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin Appl 3:1052–1061Google Scholar
  13. 13.
    Halim A, Nilsson J, Rüetschi U, Hesse C, Larson G (2012) Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD. Mol Cell Proteomics 11Google Scholar
  14. 14.
    Khadjavi A, Barbero G, Destefanis P, Mandili G, Giribaldi G et al (2011) Evidence of abnormal tyrosine phosphorylated proteins in the urine of patients with bladder cancer: the road toward a new diagnostic tool? J Urol 185:1922–1929Google Scholar
  15. 15.
    McDonald WH, Yates JR, 3rd (2002) Shotgun proteomics and biomarker discovery. Dis Markers 18:99–105Google Scholar
  16. 16.
    Chen T, Xie G, Wang X, Fan J, Qiu Y et al (2011) Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 10:M110 004945Google Scholar
  17. 17.
    Wu T, Du Y, Han J, Singh S, Xie C et al (2013) Urinary angiostatin—a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics 12:1170–1179Google Scholar
  18. 18.
    Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S et al (2008) Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 17:1034–1042Google Scholar
  19. 19.
    Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C et al (2012) Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax 67:502–508Google Scholar
  20. 20.
    Thomas CE, Sexton W, Benson K, Sutphen R, Koomen J (2010) Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiology Biomarkers & Prevention 19:953–959Google Scholar
  21. 21.
    Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S et al (2004) Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 65:2426–2434Google Scholar
  22. 22.
    Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K et al (2009) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 8:268–281Google Scholar
  23. 23.
    Lankisch P, Wessalowski R, Maisonneuve P, Haghgu M, Hermsen D et al (2006) Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr Blood Cancer 46:767–772Google Scholar
  24. 24.
    Lemm G, Kuppers J, Frey R, Wingender W, Kuhlmann J (1998) Monitoring of proteinuria in phase I studies in healthy male subjects. Eur J Clin Pharmacol 54:287-294Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.National Key Laboratory of Medical Molecular Biology, Department of PathophysiologyInstitute of Basic Medical Sciences, Chinese Academy of Medical Sciences/School of Basic MedicineBeijingChina

Personalised recommendations